Skip Navigation Links
07 September 2020

OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain

OCT is a pharmaceutical company founded on the concept of harnessing the medical potential of cannabinoids, and this has been at the heart of our motivation in the ensuing years. With this central mission of OCT in mind, we assessed the licensed medicines and unlicensed medical cannabis business models when we set out, to ensure that we took the path that would allow us to maximise the potential health benefits of cannabinoids while ensuring the highest degree of product safety and efficacy. There are some important differences between the two, which I set out below:

Types of Drug Products

Medical cannabis is either cannabis flower or cannabis extracts that are smoked, in the case of flower, vaped or orally ingested. The extracts may be in the form of a purified phytocannabinoid (e.g. CBD or THC) or a mixture thereof. These extracts may further contain other compounds from cannabis, such as terpenes and flavonoids.

Any of the above products can potentially be developed as a license medicine. In addition, improved versions of cannabinoids can be developed as a licensed medicine. Natural phytocannabinoids have some drawbacks, particularly when administered orally, that can be reduced or eliminated through medicinal chemistry. This offers the licensed medicine developer a vast array of possibilities that are not available to medical cannabis.

Market Exclusivity

A limited time of market exclusivity is necessary to allow drug maker to recoup the expense of development and provide a reasonable return on investment. Licensed drug makers can obtain market exclusivity through patents and regulatory exclusivity. Patents provide the owner with 20 years of market exclusivity. To obtain a patent, an invention such as a drug compound must be both novel and unobvious. New cannabinoid derivatives with improved drug-like properties may qualify for patent protection. Natural medical cannabis products, on the other hand, are generic by nature. Agencies that regulate medicines (e.g. FDA, MHRA and EMA) grant a limited period of exclusivity for new medicines. Regulatory exclusivity is also available for medicines that are developed for orphan indications. Since medical cannabis is not regulated by these agencies, regulatory exclusivity is unavailable.

Marketing

Licensed drug products can be indicated and marketed for approved indications. On the other hand, medical cannabis cannot make any claims to treating a disease or condition. This leaves both doctors and patients guessing as to whether a medical cannabis product is both safe and effective for their disease or condition.

By Prescription

Our aim as a pharmaceutical company is to develop prescription medicines for indications where there is a significant unmet medical need. These are indications where patients are diagnosed and treated by a physician. In the US, physicians are not permitted to prescribe unlicensed drug products, including medical cannabis. This leaves the patient to self-prescribe and dose a medical cannabis product that may be contraindicated for their condition or have drug-drug interactions with medicines prescribed by their doctor.

Reimbursement

Crucially, we wanted patients who could be treated with our medicines to be able to be reimbursed. While patients will usually have to pay out of their own pocket for medical cannabis, insurance companies will generally cover licensed medicines, allowing patients the peace of mind that their treatment will be paid for, so this ticked another box for us.

Legalisation of Cannabis

The ever-changing legal status of cannabis and cannabis-related products add a significant degree of uncertainty to medical cannabis producers. In the US, medical and adult use cannabis is regulated at the state level, with regulations varying from state to state.

Changes in cannabis-related legislation does not impact a licensed medicine business model as licensed medicines are regulated by FDA and other medicines regulatory agencies.

Regulation ensures Safety and Efficacy

When comparing the licensed medicines to unlicensed medical cannabis business models, it was abundantly clear which model OCT would follow. By far the most important reason for selecting the licensed medicines model was because of the higher regulatory standards imposed for licensed drug products. FDA and other regulatory agencies learned, often through tragic events, that the only definitive way of demonstrating a drug product is both safe and effective is through rigorous preclinical testing and randomised controlled clinical trials. We were adamant that physicians and patients must have assurance that our drug products are both safe and effective and produced in a quality and dose consistent manner.

We think you will see why it was obvious to us that the licensed medicines route to market was the right choice for OCT to take. If you are unsure though, the next time you open your medicine cabinet ask yourself: does it matter that my medicine has undergone rigorous preclinical testing and randomised controlled clinical trials to demonstrate that it is safe and effective?

 

Author: John Lucas

Related News articles

  • Oxford Cannabinoid Technologies nearly ready for new Phase 1 trial

    14 November 2022 Proactive Interview
  • StockBox Premiere - Oxford Cannabinoid Technolgies - Programme 1

    06 October 2022 StockBox
  • StockBox Interview - Oxford Cannabinoid Technologies w/ Dr Valentino Parravicini, CSO

    05 October 2022 StockBox
  • StockBox Premiere with Oxford Cannabinoid, Poolbeg Pharma & Destiny Pharma

    05 October 2022 StockBox
  • Cannabinoid Medicine for Pain Treatment with Clarissa Sowemimo-Coker COO Oxford Cannabinoid

    22 August 2022 StockBox
  • Oxford Cannabinoid Technologies has good opportunities in both lead products says analyst

    26 July 2022
  • Outsourcing in Clinical Trials UK & Ireland 2022 Conference – Dr Valentino Parravicini’s Address

    20 June 2022 Conference
  • OCT Investor Update 30 May 2022 - Q&A Questions

    30 May 2022 Investor Questions
  • The Cannabis Conversation: Cannabis Vs. Opioids with Valentino Parravicini

    18 May 2022 Podcast
  • Investor Meet Company Q&A Session

    16 May 2022 Investor Meet
  • Oxford Cannabinoid Technologies Announces Formation of Scientific Advisory Board to Support Clinical Strategy

    25 April 2022 Scientific Advisory Board
  • Updates on Lead Programme 1 (OCT461201) and Programme 2 (OCT130401) - Trigeminal Neuralgia Clinical Trial

    31 March 2022 Programme Update
  • Data from pre-clinical study show positive results

    08 March 2022 Research Update
  • Requisition of General Meeting - Update

    04 March 2022 General Meeting
  • Oxford Cannabinoid Technologies aims to get aggressive share of £42.5bln market by 2027

    24 February 2022
  • Requisition of General Meeting

    18 February 2022 General Meeting
  • Notice of Analyst and Investment Presentation - How to Register

    17 February 2022 Presentations
  • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

    18 November 2021 StemTech
  • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

    17 November 2021 R&D Support
  • Posting of Annual Report, Notice of AGM and Form of Proxy

    27 October 2021 Annual Report, Notice of AGM and Form of Proxy
  • OCT Results and Company Update

    18 October 2021 Results and Company Update
  • Final Results and Notice of Annual General Meeting 13th October 2021

    13 October 2021 RNS
  • Oxford Cannabinoid Technologies work on treatment for chronic, painful disease Trigeminal Neuralgia

    12 October 2021 Trigeminal Neuralgia Interview
  • Oxford Cannabinoid Technologies Targets Chronic Pain Condition with Latest Formulation

    11 October 2021 Program 2 Announcement
  • OCT Explore the Opioid Crisis and Chronic Pain Pandemic in Pharmafocus Magazine

    30 September 2021 Pharmafocus Article
  • Good shape, good budget and on track for Oxford Cannabinoid Technologies Holdings

    28 September 2021 Podcast
  • Oxford Cannabinoid Technologies' deal for exclusive access to Canopy Growth's cannabinoid library

    22 September 2021 Canopy Growth
  • Oxford Cannabinoid Technologies says admission to the OTCQB is a logical next step

    02 September 2021 US Market
  • Oxford Cannabinoid Technologies announces strategic partnership with Evotec

    06 July 2021 Partnership
  • Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

    Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

    24 June 2021 iCDP Speaker
  • Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

    Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

    22 June 2021 Meet the Team Interview Series
  • Oxford Cannabinoid Technologies Holdings plc to conduct live presentations to retail investors

    04 June 2021 Live Presentation
  • OCT Forges Partnership with Voisin Consulting Life Sciences

    OCT Forges Partnership with Voisin Consulting Life Sciences

    01 June 2021 OCT Partnership
  • Oxford Cannabinoid Technologies Announces Changes to Executive Team

    11 January 2021 Oxford Cannabinoid Technologies Announces Changes to Executive Team
  • OCT Company Values: How We Pursue Our Mission and Vision

    OCT Company Values: How We Pursue Our Mission and Vision

    01 December 2020 OCT Company Values
  • OCT - Meet the Team Interview Series: Valentino Parravicini, Chief Scientific Officer

    Meet the Team Interview Series: Dr Valentino Parravicini, Chief Scientific Officer

    26 October 2020 Meet the Team Interview Series
  • OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain

    07 September 2020 OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain
  • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

    OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

    28 July 2020 OCT Press Release
  • Cannabinoids in medicine part 5: Treating COVID-19

    17 June 2020 Open Access Government
  • Why the Government should continue to invest in Life Sciences post COVID-19

    Why the government should continue to invest in Life Sciences post COVID-19

    01 June 2020 OCT blog - John Lucas, COO
  • OCT researchers publish new study examining genes involved in treating neuropathic pain

    19 April 2020 OCT Press Release
  • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

    03 April 2020 OCT Press Release
  • Cannabinoids in medicine part 4: Epilepsy

    30 March 2020 Open Access Government
  • Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

    07 January 2020 Open Access Government
  • Cannabinoids in medicine Part 2: Pain

    11 October 2019 Open Access Government
  • Cannabinoids in medicine Part 1: Cancer

    22 August 2019 Open Access Government
  • An interview with Neil Mahapatra

    08 January 2019 The Times Magazine
  • High life: the start-up hoping to unlock the secrets of medical cannabis

    09 August 2018 Evening Standard
  • Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

    28 June 2018 OCT Press Release
  • Embracing the medical potential of cannabinoids

    01 June 2017 The Medicine Maker
  • Smashing the stigma with science

    01 June 2017 The Medicine Maker
  • Oxford University launches £10m research project into medical marijuana

    16 March 2017 Evening Standard
  • Oxford University launches £10m marijuana research programme

    16 March 2017 BBC
  • Oxford University to launch multimillion-dollar medical marijuana research program

    16 March 2017 CNBC
  • Oxford University to launch study on medical benefits of marijuana

    16 March 2017 The Telegraph
  • The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme

    15 March 2017 OCT Press Release